Clinical trial
Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET…
NCT00339157 · Institut National de la Santé Et de la Recherche Médicale, France, Other · Completed
Key facts
| NCT number | NCT00339157 |
|---|---|
| Title | Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS |
| Official title | ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS) |
| Lead sponsor | Institut National de la Santé Et de la Recherche Médicale, France, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Systemic-Onset Juvenile Idiopathic Arthritis |
| Intervention type | Biological, Drug |
| Interventions | Anakinra, Pneumo23 |
| Enrollment | 24 |
| Start date | Jun 1, 2006 |
| Completion | Jul 1, 2008 |
| First posted | Jun 20, 2006 |
| Last update posted | Jul 20, 2010 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: